Which has better earnings and valuation, MDAI or PDEX?

Pro-Dex has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spectral AI $19.65M 2.77 -$7.57M -$0.53 N/A Pro-Dex $66.59M 3.04 $8.98M $3.62 17.51

Is MDAI or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Spectral AI's net margin of -85.58%. Pro-Dex's return on equity of 22.78% beat Spectral AI's return on equity. Company Net Margins Return on Equity Return on Assets Spectral AI -85.58% N/A -72.97% Pro-Dex 16.08% 22.78% 14.30%

Is LUCD or MDAI more profitable?

Spectral AI has a net margin of -85.58% compared to Lucid Diagnostics' net margin of -876.72%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Spectral AI -85.58% N/A -72.97%

Is MDAI or RXST more profitable?

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Spectral AI -85.58% N/A -72.97% RxSight -36.58% -17.01% -15.12%

Is APYX or MDAI more profitable?

Apyx Medical has a net margin of -16.40% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Apyx Medical's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -16.40% -88.47% -14.94% Spectral AI -85.58% N/A -72.97%

Spectral AI (MDAI) Competitors

$1.71 -0.02 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 +0.03 (+1.75%)

As of 07:55 PM Eastern

Compare

MDAI vs. PDEX, LUCD, SMTI, RXST, and APYX

Should you buy Spectral AI stock or one of its competitors? MarketBeat compares Spectral AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral AI include Pro-Dex (PDEX), Lucid Diagnostics (LUCD), Sanara MedTech (SMTI), RxSight (RXST), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry.

How does Spectral AI compare to Pro-Dex?

Spectral AI (NASDAQ:MDAI) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Pro-Dex has a net margin of 16.08% compared to Spectral AI's net margin of -85.58%. Pro-Dex's return on equity of 22.78% beat Spectral AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Pro-Dex	16.08%	22.78%	14.30%

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 13.7% of Spectral AI shares are held by company insiders. Comparatively, 45.9% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spectral AI has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

In the previous week, Pro-Dex had 2 more articles in the media than Spectral AI. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company	Overall Sentiment
Spectral AI	Neutral
Pro-Dex	Neutral

Spectral AI currently has a consensus price target of $4.00, indicating a potential upside of 133.92%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 10.43%. Given Spectral AI's higher possible upside, research analysts plainly believe Spectral AI is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.77	-$7.57M	-$0.53	N/A
Pro-Dex	$66.59M	3.04	$8.98M	$3.62	17.51

Summary

Pro-Dex beats Spectral AI on 11 of the 14 factors compared between the two stocks.

How does Spectral AI compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 13.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lucid Diagnostics currently has a consensus target price of $4.19, suggesting a potential upside of 306.55%. Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lucid Diagnostics' average media sentiment score of 0.00 equaled Spectral AI'saverage media sentiment score.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
Spectral AI	Neutral

Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Spectral AI has higher revenue and earnings than Lucid Diagnostics. Spectral AI is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	44.41	-$58.01M	-$0.47	N/A
Spectral AI	$19.65M	2.77	-$7.57M	-$0.53	N/A

Spectral AI has a net margin of -85.58% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Spectral AI	-85.58%	N/A	-72.97%

Summary

Lucid Diagnostics beats Spectral AI on 7 of the 13 factors compared between the two stocks.

How does Spectral AI compare to Sanara MedTech?

Spectral AI (NASDAQ:MDAI) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Spectral AI has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.77	-$7.57M	-$0.53	N/A
Sanara MedTech	$103.12M	1.93	-$37.56M	-$3.77	N/A

In the previous week, Sanara MedTech had 2 more articles in the media than Spectral AI. MarketBeat recorded 2 mentions for Sanara MedTech and 0 mentions for Spectral AI. Sanara MedTech's average media sentiment score of 2.00 beat Spectral AI's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Spectral AI	Neutral
Sanara MedTech	Very Positive

Spectral AI has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Spectral AI currently has a consensus price target of $4.00, suggesting a potential upside of 133.92%. Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 56.32%. Given Spectral AI's higher probable upside, equities research analysts plainly believe Spectral AI is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Sanara MedTech has a net margin of -31.23% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Sanara MedTech	-31.23%	-3.19%	-0.56%

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 13.7% of Spectral AI shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Sanara MedTech beats Spectral AI on 10 of the 17 factors compared between the two stocks.

How does Spectral AI compare to RxSight?

Spectral AI (NASDAQ:MDAI) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Spectral AI presently has a consensus price target of $4.00, indicating a potential upside of 133.92%. RxSight has a consensus price target of $9.44, indicating a potential upside of 80.93%. Given Spectral AI's stronger consensus rating and higher possible upside, equities analysts clearly believe Spectral AI is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
RxSight	-36.58%	-17.01%	-15.12%

Spectral AI has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.77	-$7.57M	-$0.53	N/A
RxSight	$134.48M	1.61	-$38.94M	-$1.13	N/A

Spectral AI has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, RxSight has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, RxSight had 1 more articles in the media than Spectral AI. MarketBeat recorded 1 mentions for RxSight and 0 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.00 equaled RxSight'saverage media sentiment score.

Company	Overall Sentiment
Spectral AI	Neutral
RxSight	Neutral

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 13.7% of Spectral AI shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Spectral AI beats RxSight on 9 of the 15 factors compared between the two stocks.

How does Spectral AI compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Apyx Medical currently has a consensus price target of $6.50, indicating a potential upside of 59.31%. Spectral AI has a consensus price target of $4.00, indicating a potential upside of 133.92%. Given Spectral AI's higher probable upside, analysts clearly believe Spectral AI is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apyx Medical has a net margin of -16.40% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
Spectral AI	-85.58%	N/A	-72.97%

Apyx Medical has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, Apyx Medical had 4 more articles in the media than Spectral AI. MarketBeat recorded 4 mentions for Apyx Medical and 0 mentions for Spectral AI. Apyx Medical's average media sentiment score of 1.05 beat Spectral AI's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Apyx Medical	Positive
Spectral AI	Neutral

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by company insiders. Comparatively, 13.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spectral AI has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	3.23	-$11.21M	-$0.22	N/A
Spectral AI	$19.65M	2.77	-$7.57M	-$0.53	N/A

Summary

Apyx Medical beats Spectral AI on 12 of the 17 factors compared between the two stocks.

Get Spectral AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDAI vs. The Competition

Export

Metric	Spectral AI	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.06M	$7.05B	$6.45B	$12.39B
Dividend Yield	N/A	1.28%	2.69%	5.83%
P/E Ratio	-3.23	48.65	24.92	23.97
Price / Sales	2.77	76.52	528.81	109.59
Price / Cash	N/A	24.78	44.82	54.51
Price / Book	-9.00	7.13	10.79	6.50
Net Income	-$7.57M	$159.20M	$3.56B	$336.88M
7 Day Performance	-6.04%	-1.41%	1.67%	-0.22%
1 Month Performance	-36.19%	-1.97%	0.43%	0.77%
1 Year Performance	-16.59%	7.94%	32.84%	31.57%

Spectral AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDAI Spectral AI	1.7718 of 5 stars	$1.71 -1.2%	$4.00 +133.9%	-21.0%	$55.06M	$19.65M	N/A	83
PDEX Pro-Dex	2.1206 of 5 stars	$62.32 -2.2%	$70.00 +12.3%	+58.9%	$203.44M	$66.59M	17.22	140	Gap Down High Trading Volume
LUCD Lucid Diagnostics	4.0461 of 5 stars	$1.02 +2.0%	$4.19 +310.5%	-18.3%	$203.07M	$4.71M	N/A	70	Gap Down
SMTI Sanara MedTech	2.7004 of 5 stars	$22.69 +3.7%	$34.00 +49.8%	-20.3%	$200.55M	$103.12M	N/A	60	News Coverage Positive News
RXST RxSight	2.5244 of 5 stars	$4.68 -2.3%	$9.44 +101.8%	-63.6%	$198.29M	$134.48M	N/A	220	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDAI) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spectral AI (MDAI) Competitors

MDAI vs. PDEX, LUCD, SMTI, RXST, and APYX

How does Spectral AI compare to Pro-Dex?

Summary

How does Spectral AI compare to Lucid Diagnostics?

Summary

How does Spectral AI compare to Sanara MedTech?

Summary

How does Spectral AI compare to RxSight?

Summary

How does Spectral AI compare to Apyx Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spectral AI (MDAI) Competitors

MDAI vs. PDEX, LUCD, SMTI, RXST, and APYX

How does Spectral AI compare to Pro-Dex?

Is MDAI or PDEX more profitable?

Do institutionals & insiders have more ownership in MDAI or PDEX?

Which has more volatility and risk, MDAI or PDEX?

Does the media refer more to MDAI or PDEX?

Do analysts rate MDAI or PDEX?

Which has better earnings and valuation, MDAI or PDEX?

Summary

How does Spectral AI compare to Lucid Diagnostics?

Do insiders and institutionals hold more shares of LUCD or MDAI?

Do analysts recommend LUCD or MDAI?

Does the media prefer LUCD or MDAI?

Which has more volatility & risk, LUCD or MDAI?

Which has higher valuation & earnings, LUCD or MDAI?

Is LUCD or MDAI more profitable?

Summary

How does Spectral AI compare to Sanara MedTech?

Which has better earnings and valuation, MDAI or SMTI?

Does the media refer more to MDAI or SMTI?

Which has more risk and volatility, MDAI or SMTI?

Do analysts recommend MDAI or SMTI?

Is MDAI or SMTI more profitable?

Do insiders & institutionals hold more shares of MDAI or SMTI?

Summary

How does Spectral AI compare to RxSight?

Do analysts prefer MDAI or RXST?

Is MDAI or RXST more profitable?

Which has preferable earnings and valuation, MDAI or RXST?

Which has more risk & volatility, MDAI or RXST?

Does the media refer more to MDAI or RXST?

Do institutionals & insiders believe in MDAI or RXST?

Summary

How does Spectral AI compare to Apyx Medical?

Do analysts recommend APYX or MDAI?

Is APYX or MDAI more profitable?

Which has more risk & volatility, APYX or MDAI?

Does the media prefer APYX or MDAI?

Do insiders and institutionals believe in APYX or MDAI?

Which has higher valuation and earnings, APYX or MDAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools